Time sensitivity has long been a defining characteristic of clinical research, and is especially so today. Many of the innovations that have bolstered recent clinical trials - eSource, mobile health apps - are aimed at responding to sponsors’ concerns over study timelines, a concern sparked by rising study costs and growing markets for certain classes of drugs and other treatments. Opportunities to reduce timelines exist in all study phases. But certain inefficiencies are particular to Phase I, as are certain time-saving strategies. Here are three of them.